PLSE's Business Model
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
| Sector & Industry | Healthcare / Medical - Instruments & Supplies |
| Website | https://www.pulsebiosciences.com |
| CEO (Chief Executive Officer) | Paul Arthur LaViolette |
| Number of Employees | |
| IPO date | May 18, 2016 |
PLSE Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 3957 Point Eden Way |
| City | Miami |
| State | CA |
| Phone | 510 906 4600 |
| Zip Code | 94545 |
| Other Identifiers | |
| CIK | 0001625101 |
| ISIN | US74587B1017 |
| CUSIP | 74587B101 |
| Open | 13.83 |
| Previous Close | 13.62 |
| Volume | 204.8 Thou. |
| Average Volume | 175.9 Thou. |
| Day’s Range | 13.61 – 14.5 |
| 52 Week Range | 12.56-25 |
| MA (50) | 14.0118 |
| MA (200) | 15.8437 |
| Market Cap | 937.2 Mil. |
| Shares Out. | 67.77 Mil. |
| Earnings Date | Mar 26, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
